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Abstract
Background: Rheumatoid arthritis is a common inflammatory autoimmune disease. Although
disease activity may be managed effectively with prescription drugs, unproven treatments such as
magnet therapy are sometimes used as an adjunct for pain control. Therapeutic devices
incorporating permanent magnets are widely available and easy to use. Magnets may also be
perceived as a more natural and less harmful alternative to analgesic compounds. Of interest to
health service researchers is the possibility that magnet therapy might help to reduce the economic
burden of managing chronic musculoskeletal disorders. Magnets are extremely cheap to
manufacture and prolonged treatment involves a single cost. Despite this, good quality scientific
evidence concerning the safety, effectiveness and cost-effectiveness of magnet therapy is scarce.
The primary aim of the CAMBRA trial is to investigate the effectiveness of magnet therapy for
relieving pain and inflammation in rheumatoid arthritis.
Methods/Design: The CAMBRA trial employs a randomised double-blind placebo-controlled
crossover design. Participant will each wear four devices: a commercially available magnetic wrist
strap; an attenuated wrist strap; a demagnetised wrist strap; and a copper bracelet. Device will be
allocated in a randomised sequence and each worn for five weeks. The four treatment phases will
be separated by wash out periods lasting one week. Both participants and researchers will be blind,
as far as feasible, to the allocation of experimental and control devices. In total 69 participants will
be recruited from general practices within the UK. Eligible patients will have a verified diagnosis of
rheumatoid arthritis that is being managed using drugs, and will be experiencing chronic pain.
Outcomes measured will include pain, inflammation, disease activity, physical function, medication
use, affect, and health related costs. Data will be collected using questionnaires, diaries, manual pill
counts and blood tests.
Discussion: Magnetism is an inherent property of experimental devices which is hard to conceal.
The use of multiple control devices, including a copper bracelet, represents a concerted attempt
to overcome methodological limitations associated with trials in this field. The trial began in July
2007. At the time of submission (August 2008) recruitment has finished, with 70 trial participants,
and data collection is almost complete.
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Background
Need for a trial
Rheumatoid arthritis (RA) is a chronic inflammatory
autoimmune disease which typically begins to develop
between 30 to 50 years of age. It is estimated that 387,000
people in the UK have RA, with three times more women
affected than men. RA involves periodic inflammation of
the synovium in joints of the hand, wrist, foot, knee or
shoulder. This causes swelling of the joint capsule and irri-
tation of nerve endings, producing pain and resulting in
damage to both bone and cartilage. In turn this may lead
to both disability and mortality [1,2]. Favoured diagnostic
criteria are those of the American College of Rheumatol-
ogy [3].
The burden which RA imposes upon both the UK
National Health Service (NHS) and the economy in gen-
eral is considerable. It is reported that over just a one year
period (1999 to 2000) inflammatory arthritis accounted
for 1.9 million GP consultations, 45,887 hospital admis-
sions and a loss of £833 million in productivity [1]. For
the individual the consequences of RA may be devastat-
ing.
Treatment of RA is currently dominated by the use of
medication. Non steroidal anti-inflammatory drugs
(NSAIDs), including second generation Cox-2 inhibitors,
together with disease modifying anti-rheumatic drugs
(DMARDs) are the most widely used pharmacological
agents for managing RA [4]. However recently developed
biological agents, including TNF-α antagonists, have also
been found to prevent damage and are becoming more
widely prescribed [5]. Whilst such drugs may alter disease
progression, people with arthritis rarely find that they are
entirely adequate for the purpose of pain control. There-
fore analgesics are also typically prescribed as an adjunct
[6].
The fact that all commonly prescribed drugs for rheuma-
toid arthritis are associated with unwanted side effects is
worrying for both practitioners and patients. For example,
DMARDs are associated with high levels of toxicity and
therefore cannot be tolerated for long periods [5]. Moreo-
ver, NSAIDs have been shown to cause gastrointestinal
ulcers, which may result in perforation, bleeding and
death [4,7,8].
Over recent years health professionals have witnessed a
patient led revolution in the use of complementary and
alternative medicine (CAM). Whilst reliable estimates for
CAM use are hard to obtain, results from a fairly recent
population based survey indicated that around 28% of
the UK adult population use some form of CAM in just
one year [9]. However, it has also been shown that people
who experience chronic pain are twice as likely to try CAM
[10]. One might therefore anticipate that patients with RA
would be included amongst this group. Indeed, this
appears consistent with suggestions that almost 60% of
people with arthritis use complementary therapy [11]. In
part, such popularity may also be attributed to the percep-
tion, albeit sometimes misguided, that complementary
therapies lack side effects and therefore represent a safe
and 'natural' alternative to drugs [4,12]. Alternatively this
may simply relate to a rise in holistic attitudes [10,13].
Whatever the case, such treatments have typically been
viewed with scepticism by the medical community. Yet
assumptions which directly equate lack of previous scien-
tific evidence to lack of therapeutic efficacy should be
challenged. Rather attention should be drawn to the fact
that until recently CAM accounted for less than 1% of
total research budgets [14]. This being a figure which is
grossly disproportionate to the measurable contribution
which CAM makes towards first-contact primary care [9].
With a growing emphasis on patient choice [15], CAM is
now becoming recognised as a largely untapped resource
which offers the potential for therapeutic innovation
within the NHS. This view is supported by both the House
of Lords and the UK government, which have recom-
mended a major increase in funding for CAM research
[13,16].
Perhaps one of the most intriguing yet under researched
forms of CAM is that of magnet therapy. Quite simply it
involves the application of magnetic materials on or very
close to the skin over prolonged periods of time. This
encompasses a wide range of interventions involving dif-
ferent types of devices, different strength magnetic fields
and different modes of administration [17]. For example,
devices may be unipolar, in which case only one magnetic
pole faces towards the skin, or bipolar when two or more
magnets are used which face in opposite directions [18].
However magnet therapy should not be confused with
pulsed magnetic field therapy, which involves brief expo-
sure to much stronger electromagnetic fields.
Fascination with the potential health benefits of magnetic
forces dates back to antiquity, although in recent times
this topic has received a resurgence of public interest [19].
Magnet therapy now appears to be one of the most widely
used forms of CAM for the management of chronic pain
associated with musculoskeletal disorders such as RA,
with many patients demonstrating willingness to pri-
vately purchase permanent magnetic devices which are
marketed for health purposes. Indeed, it has been esti-
mated that the worldwide sales of such devices account
for somewhere between one and four billion US dollars
each year [20,21].Trials 2008, 9:53 http://www.trialsjournal.com/content/9/1/53
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Whilst such devices are widely claimed to help alleviate
pain for a range of disorders, there appears to be no clearly
identified mechanism of action, although theoretically
this might involve a reduction in inflammation [18]. Sci-
entific evidence relating to the effectiveness of magnet
therapy is however reported to be equivocal [22]. This has
lead to calls for larger and more rigorous randomised con-
trolled trials (RCTs) to determine the actual therapeutic
effectiveness, safety and cost-effectiveness of magnet ther-
apy for specific pathological conditions [17,23].
The placebo problem
Perhaps the greatest methodological challenge faced by
trials of magnet therapy is that of providing adequate con-
trol devices against which any 'true' effects from magnet
therapy may be assessed. RCTs which incorporate a pla-
cebo control group are generally perceived as methodo-
logically superior to those which do not. This is especially
the case for trials involving new treatments and subjective
outcome measures [24,25]. The key methodological
advantage of placebo controlled trials over open trial
designs relates to the ability to blind participants, clini-
cians and researchers to the allocation of experimental
and control treatments [26]. This helps to avoid system-
atic bias resulting from differences in the perceived or
desired effectiveness of treatments which may alter the
outcomes being assessed [27-29].
For trials of magnet therapy successful blinding is ham-
pered by the fact that magnetism is a necessary quality of
experimental devices which can in most cases be detected
with relative ease. Trials which report superior patient out-
comes for a magnetic device as opposed to a non-mag-
netic control device are therefore likely to be criticised on
the basis that results may be attributable to non-specific
(placebo) effects [30,31]. This highlights the need to eval-
uate success of blinding [25].
The problem of blinding is not necessarily without solu-
tion however. One approach is to use an attenuated con-
trol device, which retains a weak magnetic force and
therefore helps to prevent participants and researchers
from correctly identifying the device as a placebo or sham
[32,33]. One limitation of this approach however is that
rather than being completely inert the control device may
have some therapeutic action. As such, this may produce
a more conservative estimate of treatment effect between
groups.
An alternative approach, yet to be reported, is to use a
non-magnetic comparator which is marketed commer-
cially as having similar therapeutic benefits, but which in
truth is ineffective. Such a device would need demonstrate
equivalent face validity, i.e. be perceived as equally credi-
ble in terms of anticipated therapeutic effects. It should
also be used in a similar fashion to the experimental mag-
netic device. For trials which seek to evaluate magnetic
wrist straps, copper bracelets might serve as a suitable pla-
cebo.
Copper bracelets
Copper bracelets are often worn by people who suffer
with arthritis in the belief that they may help to prevent
inflammation and pain. Whilst research findings point
towards serum copper imbalances in patients with arthri-
tis [34-36], it is likely that this reflects a natural metabolic
response, rather than a cause of inflammation [37]. A pro-
posed link between dermal copper absorption and pain
relief in arthritis may therefore be rather tenuous. How-
ever, given the popular use of copper bracelets it is surpris-
ing that no rigorous scientific research appears to have
been conducted on the effectiveness of such devices.
In the most widely cited study on this topic, Walker and
Keats randomised 240 arthritis sufferers into three groups
[[38], see also [39]]. Group 1 wore a copper bracelet for
one month and then an aluminium bracelet for a further
month. Group 2 wore identical devices but in reverse
order and Group 3 wore no device. From this Walker and
Keats reported that significantly more participants rated
the copper bracelet as superior than the aluminium
bracelet and that copper bracelets actually lost weight by
an average of 13 mg/month. This appears to support the
theory that copper may be leached into the skin and that
this may have had a positive therapeutic effect on arthritis
symptoms. However, Walker and Keats failed to demon-
strate any positive correlation between the weight loss of
individual bracelets and perceived efficacy. Major criti-
cisms of this study centre on selection bias and measure-
ment error. For example, 163 or 68% of all participants
were excluded from the analysis. Some of whom were
removed due to poor compliance, whilst others were
excluded on the grounds that their bracelets were
observed to have gained weight. It is not surprising there-
fore that the remaining bracelets included in the analysis
were reported to have lost weight. Blinding is also likely
to have been compromised since the control bracelet
would have appeared different in weight, colour and cor-
rosion. As such, these findings have yet to be replicated
elsewhere.
More compelling evidence to refute a possible link
between dermal copper absorption and pain relief in
arthritis comes from Shackel and colleagues, who
reported findings from a seemingly well conducted dou-
ble-blind placebo-controlled trial [40]. In this study 116
participants were randomly allocated to receive either
copper-salicylate gel or a placebo gel, which they applied
daily over a one month treatment period. Whilst one
would expect copper to be absorbed more readily from aTrials 2008, 9:53 http://www.trialsjournal.com/content/9/1/53
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topical preparation than a copper bracelet, findings from
this trial failed to show any difference between the cop-
per-salicylate gel and the placebo gel in terms of pain
relief, ratings of treatment efficacy or medication use. Yet
the extent to which these findings may be generalised to
patients with RA also is open to question.
Systematic reviews
A review of scientific databases (Cochrane Library,
Medline, AMED and CINAHL) up to July 2007 confirmed
an overall paucity of rigorous scientific research into the
therapeutic effectiveness of magnet therapy for RA, or any
other specific disorder. Whilst a number of critical reviews
have been published concerning magnet therapy [e.g.
[17,41]], these have attempted to answer the same basic
question, i.e. whether or not magnet therapy is effective
for pain control. Such reviews have therefore tried to com-
bine data relating to a wide spectrum of different pain
related disorders and have also incorporated studies in
which pain has been experimentally induced. Moreover,
major inconsistencies between studies in terms of inter-
vention (e.g. according to the magnetic strength of devices
used and also exposure periods involved) has further
served to obscure any clear findings. As yet no obvious
attempt has been made to undertake a systematic review
specifically concerned with the effects of magnet therapy
for people with arthritis.
Previous trials of magnet therapy for rheumatoid arthritis
To the authors' knowledge only one previous RCT has
focused specifically on the effects of magnet therapy for
patients with RA. Segal and colleagues randomly allocated
64 patients with RA of knee to wear either a bipolar mag-
netic device (MagnaBloc®) or a seemingly identical unipo-
lar device [32]. The experimental device consisted of four
magnets disks (each 1900 Oersteds) whereas the control
device included just one magnetic disk (720 Oersteds)
and three non-magnetic disks. Devices were attached to
the knee for a period of one week in both the treatment (n
= 38) and control (n = 26) groups. Both participants and
researchers were reportedly blind to treatment allocation.
Although participants allocated to the MagnaBloc® group
demonstrated a statistically greater reduction in pain
throughout the intervention phase than those in the con-
trol group, the study failed to demonstrate a statistically
significant difference in pain between the two groups at
the end of the 1 week period (p = 0.23). In terms of surro-
gate measures of inflammation (C-reactive protein and
erythrocyte sedimentation rate) no difference was
observed between treatment and control groups. In the
absence of any evaluation of success in blinding, it is
interesting to note that participants global assessment of
disease activity improved to a significantly greater extent
in the treatment group than in the control group (p <
0.01).
Whilst results presented by Segal and colleagues may be
challenged on the basis of poor trial design and lack of sta-
tistical power, this study nevertheless highlights a number
of other methodological weaknesses which characterise
other published trials of magnet therapy. Importantly,
medication use was not measured although participants
were likely to alter their use of analgesics as a response to
changes in pain intensity. Any true benefit derived from
magnet therapy may therefore have been masked by a
reduction in medication use. In order to provide a prag-
matic evaluation of effectiveness, trials of magnet therapy
should offer participants the opportunity to use devices in
a manner which reflects real world behaviour. Since mag-
net therapy is generally understood to involve prolonged
periods of exposure to magnetic fields, any short term
experimental intervention may prove insufficient in order
to demonstrate a cumulative therapeutic effect. In the case
of the trial described by Segal and colleagues, an exposure
period of just one week may well have been inadequate.
Information on compliance was also omitted, providing
little assurance that trial participants actually wore the
devices they were given. Even if data are to be analysed by
intention to treat rather than by active treatment, informa-
tion concerning compliance will still be of value.
Pilot trial (MACROPOD)
The proposed study builds upon methodology employed
in an earlier RCT, referred to as the MACROPOD trial,
which was designed and led by the present author.
MACROPOD (ISRCTN 18518978) was a randomised
double-blind placebo-controlled crossover trial of magnet
therapy for pain relief in osteoarthritis. In total 45 partici-
pants were randomly allocated to one of four treatment
sequences consisting of four phases, with each phase last-
ing one month. Participants each wore a full strength
bipolar magnetic bracelet (mean strength 2009 Oersteds,
SD 177), an attenuated bracelet (453 Oersteds, SD 120),
a non-magnetic bracelet and a copper bracelet. Outcomes
measures included the WOMAC 3.1 Osteoarthritis Index
(which covers pain, physical function and stiffness), for
which the pain subscale was selected as the primary out-
come measure. The trial also incorporated the McGill Pain
Questionnaire and the EQ-5D. Medication use was calcu-
lated by triangulation of diary records, prescription
records and by manually counting remaining tablets and
capsules before and after each phase. Economic data con-
cerning the use of health care resources were collected in
order to facilitate future cost-effectiveness analyses.
Whilst originally conceived as a pilot RCT, MACROPOD
was nevertheless developed in order to achieve sufficient
statistical power to demonstrate a meaningful clinical dif-
ference in pain outcomes between the commercially avail-
able magnetic device and the three 'placebo' devices.Trials 2008, 9:53 http://www.trialsjournal.com/content/9/1/53
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Findings from the MACROPOD trial have been summa-
rised elsewhere [42] and are currently being prepared for
publication in greater detail. In terms of methodology, the
MACROPOD trial served to demonstrate feasibility for a
larger and somewhat more comprehensive RCT. In partic-
ular, the use of multiple control devices appeared to rep-
resent a useful and valid approach in helping to address
the problem of adequate placebo control. It is neverthe-
less worthwhile noting that MACROPOD concerned oste-
oarthritis rather than rheumatoid arthritis, and that no
biological outcome measures were employed.
Ongoing trials
A search of The Cochrane Central Register of Controlled
Trials (CENTRAL) and the metaRegister of Controlled Tri-
als (mRCT) conducted in July 2007 indicated that no
other RCTs of magnet therapy for arthritis were in progress
at this time.
Objectives
The proposed trial will investigate the therapeutic effec-
tiveness of magnet therapy when used as an adjunct to
practitioner led management of pain and inflammation
in rheumatoid arthritis. Possible effects on other major
health outcomes will also be considered. This will involve
a comparison of treatment effects between a commercially
available magnetic device and three control devices,
which are intended to act as placebos. This addresses a
need for rigorous scientific evidence on the subject.
General objective
To investigate the therapeutic effects of wearing a widely
available permanent static magnetic device for patients
with RA.
Specific objectives
1. To determine the actual therapeutic effectiveness of a
magnetic wrist strap in terms of the following outcomes:
￿ pain
￿ inflammation
￿ functional status
￿ general health
￿ quality of life
￿ use of medication
Note: Specific outcomes assessed will be used to provide a
composite measure of disease activity.
2. To identify specific factors that may predict or mediate
therapeutic effects of magnet therapy.
3. To identify any specific factors which mediate observed
placebo effects.
4. To evaluate the therapeutic effectiveness of copper
bracelets, and their potential role as placebos in magnet
therapy research.
5. To report any adverse events or reactions relating to the
use of devices employed.
6. To gather economic data that could be used to evaluate
the cost-effectiveness of magnet therapy.
Methods
Design
The trial will employ a randomised crossover design.
Therefore each participant will act as his or her own con-
trol. The principle advantage of a crossover design is that
error variance is reduced, thereby minimising the sample
size required. Crossover designs are also extremely well
suited to exploratory research of new treatments [43].
Population
Patients will be suffering with rheumatoid arthritis and
also receiving active treatment within a primary care set-
ting.
Inclusion criteria
1. 18 years of age or over.
2. Diagnosis of rheumatoid arthritis within medical
records.
3. Currently prescribed analgesic medication, NSAIDs or
DMARDs.
4. Chronic pain: either persistent or intermittent over a
minimum period of three months prior to recruitment
[44].
5. Current pain: greater than 30/100 mm on a pain visual
analogue scale (VAS) within the last 24 hours despite
medication.
Exclusion criteria
1. Pregnancy.
2. Pacemaker or similar device.
3. Not responsible for administering his/her own medica-
tion.Trials 2008, 9:53 http://www.trialsjournal.com/content/9/1/53
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4. Dementia or memory impairment, either documented
in medical records or if suspected indicated by a score of
6 or below on the Abbreviated Mental Test [45].
5. Diagnosis of malignant disease within medical records.
6. Forthcoming orthopaedic surgery within the next 25
weeks.
7. Known allergy to copper.
8. Regular use of a magnetic or copper device at recruit-
ment.
Within the proposed trial it would neither be desirable,
practical nor ethical to limit recruitment to patients who
are either not prescribed, refuse or stop drug treatments in
order to participate in the study. In particular, the trial
attempts to evaluate the effectiveness (rather than effi-
cacy) of magnet therapy within a real world context. Most
people with verified and active RA will be taking medica-
tion. Recruitment of sufficient patient numbers would
therefore prove extremely difficult if those taking medica-
tion were excluded. This would also involving a highly
selective population, severely limiting the generalisability
of results. Moreover, even those who are not taking med-
ication at the start of such a study may well alter their sta-
tus during the trial. It is also likely to be viewed as
unethical to ask patients to stop taking their medication in
order to take part in the trial. This is because the devices
involved have largely unproven therapeutic effects, are
not currently thought to alter disease progression, and
because multiple placebo devices will be used.
Interventions
Given the inherent difficulties in developing a 'perfect'
placebo for magnet therapy, this study will build upon
methodology employed within the MACROPOD trial by
incorporating one experimental and three distinct control
devices. The use of multiple control devices represents a
comprehensive and concerted attempt to overcome differ-
ent limitations associated with each individual device in
terms of blinding and potential therapeutic action. All
participants will therefore undergo four treatment phases:
Full strength MagnaMax® (experimental device)
The experimental device selected for use in this trial is the
MagnaMax® magnetic wrist strap. This is a widely available
magnetic device which is marketed for the purpose of
relieving pain in conditions such as rheumatoid arthritis.
It is representative of other commonly purchased devices
in terms of its application and magnetic strength. This
device consists of two concentric neodymium magnets
which fit together into a bracelet that is worn around the
wrist. The central magnet can be rotated 360 degrees
within the outer magnet. Similarly the outer magnet can
be reversed so that there are four possible configurations
for direct contact with the skin (+++, +-+, ---, -+-). Inserts
will be supplied to participants in an opposing configura-
tion. Both magnets are plastic coated, and the overall size
of the insert is 23 mm in diameter. A calibrated Hall effect
probe will be used to check the maximum magnetic sur-
face field strength of the inserts.
Attenuated MagnaMax® (placebo)
This will be identical to the experimental device with the
exception that the magnetic field strength of inserts will be
reduced to between 250 to 350 Oersteds. The use of a
lower limit of 250 Oersteds should ensure that the device
retains sufficient magnetism to firmly adhere to a vertical
metal surface (e.g. a refrigerator). Participants are unlikely
to identify this as a placebo, although it is possible that
the weak magnetic field produced may have some thera-
peutic effect.
Demagnetised MagnaMax® (dummy)
This will appear identical to the experimental device
although the inserts will be demagnetised, and should
therefore be entirely inert. However participants may eas-
ily identify the device as non-magnetic and therefore view
it as a placebo.
Copper bracelet (placebo)
Participants will also test a commercially available copper
bracelet. As copper bracelets are widely used for pain relief
by the general public it is thought that participants may
expect this to have some therapeutic benefit. Whether or
not this device actually represents a valid placebo is a
question which will be addressed as part of the trial.
Participants will be required to wear each of these devices
for a minimum of 12 hours per day, although continuous
use will be recommended. Participants will begin the first
treatment phase immediately after recruitment. Each
treatment phase will last five weeks and be separated by a
one week 'wash out' period. Total duration for participa-
tion will therefore be 23 weeks.
Non-compliance in terms of failure to wear devices for the
recommended amount of time is unlikely to represent a
major problem. Compliance will be measured by asking
participants how long they wore each device for and sys-
tematic bias should be avoided due to the random alloca-
tion of participants to different intervention sequences.
Whilst the present study employs placebo-control, the
emphasis is nevertheless that of a pragmatic evaluation of
the effectiveness, rather than efficacy, of magnet therapy
within a real world setting [46]. Non-compliance there-
fore represents a valid outcome in its own right.Trials 2008, 9:53 http://www.trialsjournal.com/content/9/1/53
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Randomisation
Participants will be randomly allocated to 1 of 24 possible
treatment sequences. Treatment sequences will consist of
four phases, with each phase corresponding to a particular
device (as shown in Figure 1). This method is preferred
over the use of a Latin square design, as this will help to
minimise possible analytical bias associated with attri-
tion.
Randomisation will be performed remotely and inde-
pendently by staff at the York Trials Unit using a relevant
computer programme to avoid any bias in sequence allo-
cation. Randomisation will be performed using block
sizes of 24, which should help to provide relatively even
balance in terms of the number of people allocated to
each treatment sequence. The randomisation code will be
concealed from the principal investigator until all data
collection has been completed. The randomisation
method therefore provides little scope for subversion of
the allocation process. Since each participant will test all
four devices there is also no meaningful purpose for sub-
version. Once the full randomisation sequence for all
potential participants has been determined, then devices
will be packed by a member of the York Trials Unit and
sealed in identical padded boxes, distinguishable only by
a trial ID number and order in which they are to be dis-
tributed.
Methods for protecting against bias
Several methods will be employed to counter additional
threats from bias in terms of both the internal and exter-
nal validity.
Blinding
Patients, GPs, and other health care staff will be offered
limited information about the trial. The trial will be pre-
sented as a study to evaluate the effectiveness of magnetic
and copper bracelets on arthritis symptoms. All commu-
nication will simply state that one or more of the devices
being tested might be intended to act as a placebo. At no
point will they be provided with specific information con-
cerning devices or their expected effects. Moreover partic-
ipants will not be given the opportunity to directly
compare devices.
The principal investigator will remain blind to the order
in which devices are allocated until after the completion
of data collection. Devices will be independently pack-
aged and sealed within plain white padded boxes by the
York Trials Unit. Boxes will simply bear the trial ID
number and order of distribution. Devices will then be
distributed by the principal investigator at recruitment
and at each follow-up. Each box will contain unique laser
labels bearing the trial ID number and the mark of an offi-
cial stamp. At the end of each treatment phase participants
will be instructed to remove the device before being vis-
ited by the principal investigator and to seal the device
within the padded box, using labels provided. Devices
will be collected by the researcher at the end of each visit
(i.e. after data collection) and returned to the trials unit.
The integrity of each seal will be independently inspected
and recorded. Participants will also be instructed in writ-
ing to avoid describing the device(s) they have tested in
any communication with the researcher. This procedure
will also help to ensure that all devices are returned,
thereby preventing possible contamination of treatment
effects.
Stratified random sampling
Roughly equal numbers of patients with RA should be
approached by each participating practice. Should the
number of potentially eligible patients identified within
each practice exceed the target number (i.e. 52 per prac-
tice) by more than 50% (i.e. 78) then patients will be
selected at random to receive information about the trial.
In such case, patient recruitment will involve stratified
sampling according to general practice. This should help
to achieve a fairly representative sociodemographic cross
section of the clinical population, which will add to the
generalisability of findings.
Wash out-periods
Whilst randomisation of participants to different alloca-
tion sequences, together with the collection of outcome
data at the end of each treatment phase, should help to
prevent bias associated with potential carry over effects,
wash-out periods between treatments will nevertheless be
employed. As such, each treatment phase will be sepa-
rated by a period of one week during which no device will
be worn. Wash out periods of one week were selected as
this seemed a reasonable duration by which one might
expect the effects of wearing a magnetic or copper bracelet
to wear off. This is also consistent with a previous ran-
domised crossover trial concerning the effects of static
magnets on low back pain, which used one week wash out
periods [47]. Together this should provide additional con-
fidence relating to the internal validity of findings and will
aid in the analysis of data [43].
Methods of data collection
Participants will be visited at home by the principal inves-
tigator on five occasions. Baseline data will be collected at
recruitment. Participants will then be followed up on four
further occasions, separated by intervals of six weeks.
These will occur at the end of each treatment phase.
Questionnaires will be sent to participants two to three
days before each planned follow up and then collected by
the principal investigator. Each trial participant will be
given a medication diary for each treatment phase whichTrials 2008, 9:53 http://www.trialsjournal.com/content/9/1/53
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Sequences for device allocation Figure 1
Sequences for device allocation. All 24 possible unique treatment sequences for the distribution of the four study devices. 
Each participant will be randomly allocated to one of these sequences, with the actual randomisation key being withheld from 
the principal investigator until completion of all data collection.
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they will be asked to complete on a daily basis. With the
participants help and prior consent (obtained at recruit-
ment) a 'pill count' will be conducted. This will involve
counting the remaining number of tablets or capsules that
the participant has in their possession for each analgesic,
NSAID or DMARD received on repeat prescription. Issue
dates will also be recorded. At a later stage prescription
records will be obtained from each participant's general
practice. Information from medication diaries, pill counts
and prescription histories will then be triangulated to esti-
mate medication use during each treatment phase. This
approach has been used successfully by both the RESPECT
trial and the MACROPOD trial [45,42].
Participants will be required to provide blood samples on
four separate occasions. Blood samples will be collected
by a nurse, phlebotomist or health care assistant located
within the practice, and should be taken within a two day
period either side of each planned follow-up. Administra-
tive staff within participating general practices will be
responsible for organising these appointments and send-
ing samples for analysis. Samples will be sent via normal
NHS channels to local haematology laboratories for test-
ing. Relevant trial labels will be provided for sample bot-
tles and request cards. Results will be entered into the
patient's medical records and a copy sent to the principal
investigator. Once recruited, all participants will be fol-
lowed up regardless of any failure to provide blood sam-
ples.
Practice staff will be encouraged to report any adverse
events or reactions which could be associated with wear-
ing study devices. Similarly, participants will be asked to
report such events directly to the trial and inform their GP.
Following all other data collection activities, each practice
will be visited by the principal investigator during which
prescription histories and any missing data from blood
tests will be obtained. Participants will be required to pro-
vide consent for access to medical records and the princi-
pal investigator will obtain honorary contracts for each of
the primary care trusts (PCTs) concerned.
Outcome measures
The recommended approach for assessment of outcomes
in clinical trials of treatments for RA is to examine change
according to a 'core set' of disease activity measures
defined by the American College of Rheumatology (ACR)
[3,48-50]. This consists of seven measures:
1. Tender joint count
2. Swollen joint count
3. Physician's global assessment of disease activity
4. Patient's global assessment of disease activity
5. Patient's assessment of physical function
6. Patient's assessment of pain
7. Acute phase reactant value
Three of these are self report measures (i.e. pain, physical
function and patient's global assessment of disease activ-
ity). Whilst it has shown that a pooled index of these three
measures may discriminate equally well to the 'core set' in
terms evaluating the efficacy of treatments in placebo con-
trolled trials [51], data collection will nevertheless be
guided by the full core set of measures.
Three measures rely on clinical examination (i.e. swollen
joint count, tender joint count and professional assess-
ment of disease activity). However for the CAMBRA trial,
repeated clinical assessments by a suitably qualified clini-
cian (i.e. rheumatologist) are not feasible. Instead, partic-
ipants will be asked to conduct self-assessed counts of
tender and swollen joints using pictorial mannequins
which have been validated in previous research concern-
ing rheumatoid arthritis [52]. These images will be repro-
duced by permission of the relevant authors. Similarly, a
professional assessment of overall disease activity must be
discounted. Participants will therefore be relied upon to
provide their own global assessment of disease activity
using a visual analogue scale adapted from the standard-
ised ACR patient assessment form. This will ask partici-
pants to consider all the ways that their arthritis affects
them at the present time and to indicate how well they
think they are doing on a 100 mm VAS accompanied by
verbal anchors, with "very well" at one end and "very poor"
at the other.
Changes in physical function will be assessed using the
Health Assessment Questionnaire – Disability Index,
which is a widely used and validated outcome measure.
Perhaps more importantly, the primary focus of this trial
is on the effects of magnet therapy on pain and inflamma-
tion in RA rather than overall disease activity. As such, the
primary outcome measure should be pain specific. For the
present trial a 100 mm pain visual analogue scale was
selected, as consistent with the recommended method of
pain measurement according to ACR criteria. This displays
verbal anchors indicating "no pain" at one end to "worst
pain ever" at the other. This will be worded as follows:
"How much pain have you had because of your rheumatoid
arthritis over the past week. Place a mark on the line below to
show how severe your pain has been (0 means "no pain" and
100 means "worst pain ever")". Visual analogue scales have
been widely used for quantifying pain for a range of con-Trials 2008, 9:53 http://www.trialsjournal.com/content/9/1/53
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ditions including rheumatoid arthritis and have been
shown to be adequate for this purpose in terms of reliabil-
ity, validity and sensitivity [53-55]. The McGill Pain Ques-
tionnaire will be used as a second pain outcome measure,
as this covers affective components and may also be used
to validate findings from the VAS. This will also aid com-
parison of findings with studies reported elsewhere.
Possible variation in participants' use of medication may
have a confounding effect on pain outcomes. This will
have the tendency of reducing any otherwise observable
difference between groups resulting from a true treatment
effect. Medication use during each treatment phase will
therefore be quantified. This will enable pain outcomes to
be adjusted if necessary on the basis of regression analysis.
Whilst the main emphasis will be placed on measuring
changes in the use of prescribed analgesic drugs (e.g. coc-
odamol and paracetamol), it is important to note that use
of other drug types (i.e. NSAIDs and DMARDs) will have
an impact on pain and therefore will be accounted for
also.
The final measure recommended by the ARC for evaluat-
ing changes in disease activity concerns the analysis of
acute phase reactants. Mechanisms involved in the allevi-
ation of pain in RA include reduction in inflammation of
the synovium. Widely used surrogate measures of inflam-
mation include blood tests, typically C-reactive protein
(CRP) and erythrocyte sedimentation rate (ESR). These
are referred to by the ACR as acute phase reactants.
Together these represent favoured outcome measures for
monitoring disease activity [49]. Results presented by
Segal and colleagues appear to show that ESR may show
wider variability [32], and therefore provide greater dis-
criminative power in terms of detecting treatment effects.
However plasma viscosity (PV) has now replaced ESR
within the local region in which the CAMBRA trial will be
conducted. PV may be considered as largely equivalent to
ESR, yet PV provides the advantage that blood samples do
not need to be processed as quickly as with ESR. Given
limitations associated with the sensitivity and specificity
of individual tests, both PV and CRP tests will be con-
ducted as proxies for inflammation within the proposed
trial.
Besides disease activity, additional therapeutic outcomes
are also of interest. In particular, the use of magnetic and
copper bracelets may have important consequences on a
patient's ability to cope and their emotional wellbeing.
The trial will therefore incorporate both the 5-item help-
lessness subscale of the Arthritis Helplessness Index [56],
using adapted 6-point measurement scales, and the Hos-
pital Anxiety and Depression Index as established meas-
ures of coping and affect.
The possibility that magnet therapy may alleviate pain in
chronic musculoskeletal conditions via endogenous
opiod channels has also been considered. However the
decision has been made not use blood samples for the
purpose of exploring changes in endogenous opiods, such
as beta-endorphin. This is due a number of factors, includ-
ing the fact that endorphin tests are not routinely used
within the NHS and therefore costs are prohibitive. More-
over, the requirement for additional blood samples
involving non-routine tests is likely to be viewed as unac-
ceptable by research participants.
The EQ-5D (EuroQol) will be used as a generic health out-
come measure [57]. For the proposed trial this represent a
valid outcome measures in its own right and will aid com-
parison of findings with other studies, such as MACRO-
POD. Participants will also be asked to report on their use
of health care resources and personal expenditure relating
to health care. This together with data collected using the
EQ-5D will facilitate any cost-effectiveness analysis of
magnet therapy arising from this trail.
Participants will be asked to report on compliance in
terms of time spent wearing each device, indicating the
number of days and hours that each device was worn. This
may relate to treatment effectiveness and assurance will be
required that participants actually wore the devices they
were given. However poor compliance will not be used as
a basis for exclusion from analyses.
Anticipated therapeutic effects from wearing magnetic
and copper bracelets will be measured at baseline and
compared in order to determine whether devices may be
considered equivalent in terms of perceived benefits. Par-
ticipants will be asked for both copper and magnetic
bracelets in turn "How likely do you think it is that wearing a
[device]  will help to relieve symptoms of your arthritis".
Responses will be measured using 5-point bipolar Likert
type scales, incorporating the following verbal anchors:
"Very unlikely";"Fairly unlikely";Can't decide";"Fairly
likely";and "Very likely".
Success of blinding will be assessed by asking participants
to judge whether or not each device worn was a placebo.
In order to ensure that participants understand the ques-
tion, they will first be provided with two applied defini-
tions of what constitutes a placebo. Definition 1: "In this
study a placebo is an inactive bracelet that has no therapeutic
effect, other than that caused by fooling the mind into thinking
it works". Definition 2: "A placebo can be thought of as a
'fake' or 'dummy' bracelet, which is used for comparison in
order to measure the real treatment effect of a genuine (i.e.
active) therapeutic device". Participants will then be asked
"Do you believe that the device you were asked to wear over the
past 5 weeks was a placebo?". Responses will be measuredTrials 2008, 9:53 http://www.trialsjournal.com/content/9/1/53
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using a 5-point bipolar Likert type scale, displaying the
following verbal anchors: "Definitely a placebo (i.e. inac-
tive)"; "Probably a placebo (i.e. inactive)"; "Can't decide";
"Probably not a placebo (i.e. active)"; and "Definitely not a
placebo (i.e. active)". One limitation of this approach is
that participants may differentiate between devices based
purely on perceived effects, rather than any consideration
of the device itself. A device which has a clear and genuine
therapeutic effect is therefore less likely to be judged as a
placebo than a device which has no apparent effect,
regardless of the adequacy of blinding procedures. Partic-
ipants will therefore also be questioned after completing
the trial, as to whether they noticed any differences
between devices (e.g. in terms of magnetism).
Adverse events and reactions will be monitored through-
out the trial.
Sample size
The sample size for this trial was determined using GPower
[58]. This indicated that complete data from 62 partici-
pants would provide 80% power to detect a minimal clin-
ically important improvement of 20% in pain outcomes
[49] for the full strength device using a one way analysis
of variance (p = 0.05). This assumed a mean score of 65
on a standard 100 mm pain visual analogue scale (VAS)
for the demagnetised device, with a difference of -13 for
the full strength device and -6.5 for both the attenuated
and copper devices, when compared with the demagnet-
ised device. An upper limit of 21.7 mm was set for the
common standard deviation within subjects. Estimates
for both mean and standard deviation were based on data
obtained by the MACROPOD trial, together with data pre-
sented by Segal and colleagues [32].
It is anticipated that loss to follow-up should not exceed
10%. In relation to this figure it is worthwhile noting that
just 1 participant out of 45 (2%) withdrew from the
MACROPOD trial. However the duration for participa-
tion (16 weeks) was shorter than the proposed trial. More
importantly, participants in the CAMBRA trial will be
asked to provide blood samples on successive occasions.
This may serve as a disincentive for continued participa-
tion. Efforts will be made however to continue to follow
up for participants who refuse to provide further blood
samples. Allowing for a maximum of 10% attrition from
recruitment to final data collection, 69 participants will
need to be recruited.
Recruitment
Initially the trial will seek to recruit six large general prac-
tices from three primary care trusts: 1) Hull Teaching PCT;
2) East Riding of Yorkshire PCT; 3) York & North York-
shire PCT. The selection of larger practices (e.g. those hav-
ing four or more partners) will help to ensure the
availability of a practice nurse or phlebotomist at each site
for the purpose of taking blood samples. Practice manag-
ers/practice staff will identify potentially eligible patients
from medical records with support from the principal
investigator. Administrative staff from each practice will
then contact patients by post. Each patient will be sent an
information sheet, letter of invite to participate and a
standard covering letter expressing support for the trial,
signed by one of the GPs. Patients will be asked to contact
the principal investigator if they are interested in partici-
pation. Should the six initial practices fail to identify a suf-
ficiently large number of patients with RA, then
additional practices will be recruited.
It is anticipated that approximately 312 potentially eligi-
ble patients with RA will need to be approached with
information about the trial and invited to take part. Based
on experience from previous trials and taking into consid-
eration the belief that blood samples may serve as a disin-
centive for participation, it is expected that roughly two
thirds (208) of patients will fail to respond (see Figure 2).
Patients who express an interest in taking part will receive
an appointment for the principal investigator to visit
them at home, or elsewhere if required. Appointment let-
ters will be accompanied by a copy of the consent form
and a baseline questionnaire. During the meeting the
principal investigator will offer more information about
the trial, show examples of the type of devices involved,
and answer any questions. He will then assess eligibility,
seek the patients' written consent to participate in the
trial, and collect the baseline questionnaire. At this stage
it is estimated that a further third (35) of patients will
either be found to be ineligible or decline to participate.
This should leave 69 patients who will then be entered
into the trial. Meetings will normally take place within the
patient's home as a pill count will be conducted if the per-
son is recruited. General practices will be informed after
each patient is recruited into the trial, and provided with
four dates for the collection of blood samples.
Planned analyses
Data from all participants recruited into the trial will be
included the analyses according to intention to treat.
The main statistical method to be used will follow the
basic estimators approach allowing for period effects as
described by Senn [[43] pp.171–5]. This will involve test-
ing for statistically significant differences in treatment out-
comes amongst the four devices, based upon follow up
scores from each treatment phase. Results will be reported
for the following outcomes: pain; inflammation (CRP and
PV values); swollen and tended joint counts; physical
function; general health; medication use; coping and
affect. Treatment effect estimates will be presented forTrials 2008, 9:53 http://www.trialsjournal.com/content/9/1/53
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each of the four devices together with their standard error
and 95% confidence intervals. The computer package
used for this purpose will be SPSS® and possibly also SAS®.
If magnet therapy is of any true therapeutic benefit then
one would expect to observe more favourable outcomes
following use of experimental (full strength MagnaMax®)
device, when compared with the other three control
devices. Conversely, should a significant difference be
observed with poorer outcomes for the demagnetised
dummy device than the other three devices, then this
would tend to indicate that any benefit of magnet therapy
may be attributed simply to a placebo effect. This does
however assume that most participants will identify the
demagnetised as a placebo, but fail to recognise either the
attenuated or copper bracelet as such.
Within the planned analyses a statistically significant dif-
ference (p < .05) in pain as measured by the VAS (as the
primary outcome measure) will be viewed as the critical
test of treatment effect. Whilst it is anticipated that suffi-
cient data will be gathered in order to provide 80% power
to detect a 20% relative improvement in pain VAS scores
for the experimental device, it is nevertheless important to
acknowledge that the pain VAS represents a rather simple
instrument involving sizeable measurement error, as
demonstrated by wide confidence intervals. Greater statis-
tical power should therefore be provided by other more
robust measures, such as the McGill Pain Questionnaire,
which may offer greater sensitivity in terms of demonstrat-
ing differences in outcome between devices. Moreover I
will seek to combine data gathered using a range of dis-
tinct clinical measures in order to form a single composite
index of disease activity, as is recommended by the ACR,
which will feature prominently within the planned analy-
ses.
Whilst it may be possible to pretest data for evidence of
carry over effects and to adjust effect estimates accord-
ingly, this approach is probably unnecessary. Reasonable
steps have been taken to account for possible carry over
effects. In particular, the study design incorporates one
week periods between treatment phase during which no
device is worn, known as passive wash out periods. More-
over, the study design also incorporates further active
wash out periods. Specifically, data is collected at the end
of each five week treatment phase but not at the begin-
ning. Together this would mean that any residual thera-
peutic effects following the removal of a device would
need to persist for a total period of six weeks or more in
order to affect the results of this study. This seems
unlikely. Attempts to pretest data for carry over and to
subsequently adjust for this may also be called into ques-
tion. This approach assumes that no carry over effect has
occurred if a statistical test fails to identify it. However the
limited power of statistical tests used may simply offer
false reassurance to the reader that there was no carry over
effect, when the reverse may be true (type II error) [43].
Participant flow Figure 2
Participant flow. Illustration of anticipated CONSORT dia-
gram, as used for the purpose of planning recruitment and 
data collection.
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Neither period effects nor period by treatment interac-
tions are anticipated. Period effects refer a change between
periods and within subjects which would have occurred
independently from any treatment given. Plausible period
effects in rheumatoid arthritis might arise from variations
in symptoms corresponding to seasonal changes, a reduc-
tion in symptoms following diagnosis during a flare up
(regression to the mean), or the widespread introduction
of a new wonder drug. However the possible influence of
such factors on treatment effect estimates obtained within
the CAMBRA trial is most likely obviated by the use of a
balanced randomisation procedure involving 24 unique
treatment sequences, and the fact that participants will
not all be recruited at the same time. Participants will also
be recruited from databases held by general practices, not
all of whom will be newly diagnosed or experiencing a
flare up at the start of the trial. Nevertheless, it is difficult
to anticipate all possible factors which might result in a
period effect or period by treatment interaction. Therefore
whilst the primary analysis will look at patient and treat-
ment, I intend to test for period and period by treatment
interactions using analysis of variance.
It is estimated that missing data will account for no more
than 10% of questionnaires. However the proportion of
missing data may be greater for blood test results, as this
requires participants to visit their general practice. Missing
blood test data will therefore be imputed where possible
from questionnaire data available for each participant
concerned. Unlike multiple imputation, this approach
assumes that data might not be missing at random, which
would be true if participants failed to provide blood sam-
ples only during periods when their symptoms flared up.
Where no data whatsoever are available, then this will be
left blank. Thereafter, sensitivity analysis will be per-
formed in order to determine whether any missing data
are related to treatment.
As a secondary step in the analysis, estimated treatment
effects for each of the devices will be adjusted according to
medication use, for which continuous data will be availa-
ble. The assumption here is that this variable may serve to
modify and otherwise mask the effects of treatment in
terms of all major outcomes. For example, participants
who benefit from magnet therapy may reduce their use of
analgesic medication in response, and therefore demon-
strate no apparent difference in terms of pain at follow up.
The basic approach used for this purpose will be that of
multiple regression, testing first for non-linear relation-
ships [59].
Information gathered on compliance will also be used in
order to perform an additional per protocol analysis,
excluding relevant outcome data for those participants
who failed to wear each device for the minimum recom-
mended period. In pragmatic terms the results of this
analysis are not especially important, however the may
still be relevant to future research and of interest to read-
ers. Differences in treatment effect may also be explored
according to baseline variables including; level of educa-
tion, belief in the therapeutic efficacy of magnetic and
copper bracelets, and previous use of complementary and
alternative medicine. Dangers associated with multiple
testing will be acknowledged however. Information con-
cerning success of blinding will be presented in detail and
should aid interpretation of the findings.
Further refinement to analysis plan will be sought towards
completion of the data collection stage of this trial. This
will take into consideration advice from Professor Martin
Bland. Statistical analyses will be performed at the end of
the trial only, although adverse events and reactions will
be actively monitored.
Analyses of economic data
Quality of life, medication use and data relating to health
care expenditure will be collected as part of the trial. If
magnet therapy is shown to be effective for reducing either
arthritis symptoms or medication use then a cost-effec-
tiveness analysis will be conducted. This will be lead by
staff from the Centre for Health Economics at The Univer-
sity of York.
Treatment compliance
Non-compliance in terms of failure to wear devices for the
recommended minimum of 12 hours per day is unlikely
to represent a major problem. Compliance will be meas-
ured and systematic bias should be avoided due to the
random allocation of participants to different interven-
tion sequences. Whilst the present study employs pla-
cebo-control, the emphasis is nevertheless that of a
pragmatic evaluation of the therapeutic effectiveness of
magnet therapy within a real world setting [46]. Non-
compliance therefore represents a valid outcome in its
own right.
Trial management
The Department of Health Sciences at The University of
York will act as the co-ordinating centre for CAMBRA. The
trial will be led by Stewart Richmond (SR) as the principal
investigator, who will be responsible for clinical and sci-
entific co-ordination, together with all aspects of day to
day management. Professor David Torgerson (DT) will be
responsible for managing the randomisation process, and
will serve as PhD supervisor to SR, advising on matters of
trial design and methodology. Professor Martin Bland
(MB) will serve as a statistical advisor to the trial. Dr Hugh
MacPherson (HM) will serve as an additional PhD super-
visor to SR, and will advise on matters concerning the use
and evaluation of complementary and alternative medi-Trials 2008, 9:53 http://www.trialsjournal.com/content/9/1/53
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cine. Professor Andrew Wong (UCLA, California) will also
serve as an advisor on matters concerning rheumatology.
It is anticipated that DT, MB and HM will also contribute
towards the analysis and interpretation of data, and prep-
aration of central publications arising from the trial.
A trial steering committee will be set up prior to recruit-
ment in order to review proposals for the study and over-
see progress. This will include academics, patient
representatives and at least one general practitioner with
an interest in the trial.
Ethics and research governance
The trial will be conducted in accordance with revised
Declaration of Helsinki and EC guidelines for Good Clin-
ical Practice.
Discussion
RA can be described as a common inflammatory muscu-
loskeletal disease, which represents a significant burden to
the UK health system and the economy. For the individual
its effects are both distressing and disabling. Conven-
tional drug treatments for RA may fail to control pain ade-
quately and can present a risk to the individual. As a
consequence, patients with arthritis sometimes seek com-
plementary and alternative therapeutic approaches to
pain management, such as magnet therapy. Historical
underinvestment in CAM research has however resulted
in a lack of scientific evidence concerning the therapeutic
effectiveness of such devices. Further pragmatic research,
such as that of the present trial, may therefore lead to
innovative therapeutic advances in the cost-effective man-
agement of diseases such as RA. Within this context, the
CAMBRA trial will seek to offer a meaningful scientific
evaluation of the true therapeutic value of magnet therapy
for RA using a novel methodological approach to over-
come some of the inherent challenges encountered by
research in this field.
Research on this topic appears particularly worthwhile
given that conclusive findings either way would prove
beneficial. If effectiveness can be demonstrated then mag-
net therapy may become a valuable addition to clinical
practice, improving quality of life amongst patients and
lowering demand for both consultations and specialist
referrals. Moreover, it may serve to reduce reliance on
potentially harmful drug treatments, thereby preventing
unnecessary adverse events. In economic terms it is also
worthwhile noting that one-off costs of providing mag-
netic devices are likely to be far lower than those of repeat-
edly prescribing analgesic medication. Therefore if, for
example, drug prescription costs for arthritis and related
conditions could be reduced by just 1% then this would
result in an annual saving to the NHS of roughly £3.4 mil-
lion [1]. Conversely, if this trial demonstrates that magnet
therapy is ineffective then this may serve to educate
patients and discourage further private expenditure on
such device. Perhaps most importantly however the
present study addresses an immediate need for guidance
which will benefit health professionals and assist in mak-
ing appropriate health care policy decisions.
Trial update [August 2008]
At the time of submitting this protocol for publication the
trial appears to be running well, and data collection will
shortly be coming to an end. However delays have been
encountered.
Study devices
Initial attempts were made to acquire suitable magnetic
devices from Ecoflow plc [Cornwall, UK] between April
and June 2006. This company is one of the leading distrib-
utors of magnetic bracelets in the UK. Recent findings
from a well designed randomised placebo controlled trial
appeared to demonstrate that Bioflow® wrist straps, as
supplied by this company, are effective for relieving pain
amongst patients with osteoarthritis [33]. However errors
in the manufacture of attenuated study devices, together
with difficulties in blinding participants could have
accounted for these findings [33,60]. It is all the more
unfortunate therefore that Ecoflow plc refused to supply
devices for further evaluation as part of the present trial.
In July 2006 MagnaMax Healthcare [Ontario, Canada]
agreed to supply the trial with 210 MagnaMax® magnetic
wrists straps. These devices have been used widely within
the UK and were studied previously within the MACRO-
POD trial. MagnaMax® wrist straps are similar to those
used in the study described above in terms of application
and magnetic strength, and are fairly typical of the type of
magnetic devices often worn by people with arthritis.
Manufacturing costs for these devices were met by the
trial. The devices were forwarded to Professor Kevin
O'Grady and Beth Jones at the Physics Department of
York University. Individual magnetic inserts were then
given unique ID numbers and randomly allocated to one
of three groups. The magnetic strength of each insert allo-
cated to the first group (full strength) was then measured
using a calibrated hall probe and recorded. These were
found to have a maximum surface magnetic field strength
of between 1502 and 2365 Oersteds. Inserts randomly
allocated to the second (attenuated) and third (demagnet-
ised) groups were individually subjected to reverse mag-
netic fields which reduced incrementally until all devices
in the second group had a maximum surface field strength
of between 250 to 350 Oersteds, and those in the third
group had a residual magnetic field of less than 20 Oer-
steds.Trials 2008, 9:53 http://www.trialsjournal.com/content/9/1/53
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70 plain pure copper bracelets were purchased from a
local pharmacy at trade cost. These together with the mag-
netic inserts were then passed on to Professor David Torg-
erson and Hannah Pearson at the York Trials Unit in order
to be boxed and randomised according to the trial proto-
col [see Figure 3].
Regulatory approval
Full ethical approval for the trial was granted by Hull and
East Riding Local Research Ethics Committee in February
2007, together with research governance approval shortly
thereafter from Hull Teaching PCT, East Riding of York-
shire PCT, and York & North Yorkshire PCT. Honorary
contracts for the principal investigator were obtained
from each of the NHS trusts concerned. Further R&D
approval was secured for acute trusts as required.
Trial Steering Committee
A trial steering committee was formed in May 2007,
which included academics from the University of York,
two patient representatives from York Rheumatoid Arthri-
tis Support Group and one external general practitioner.
Proposals for the study were reviewed and passed with
only minor alterations requested. The group agreed to
meet in future to monitor progress.
Recruitment
Patient recruitment began in July 2007 and finished in
March 2008. In total 70 people with RA were recruited,
most of whom have now completed all aspects of the
study. Participants were recruited from eight out of nine
medical practices that had agreed to support the study.
Whilst sufficient numbers of patients were recruited into
the trial in order to exceed the required sample size, the
entire process of recruitment took longer than anticipated.
This may be attributed to several factors, including an
apparent reluctance amongst most medical practices
approached to offer active support for the trial. Practice
managers and general practitioners from 34 different
medical practices were contacted in turn between June
2007 and January 2008 with written and verbal requests
for support. Staff from 25 of these practices chose not to
support the trial. Lack of available staff time was the most
frequently cited reason for making this decision. Notably
the timing of practice recruitment did coincide with a
regional outbreak of norovirus together with the annual
influenza vaccination programme. This appeared to have
placed considerable strain the resources of general prac-
tices, and in particular the workload of practice nurses.
The perceived absence of any meaningful financial incen-
tive also appeared to have played a deciding role for a
small number of practices that declined to help.
One further reason for extending the recruitment period
was that there were fewer suitable patients within each
practice than initially predicted, which led to the inclu-
sion of additional practices from further afield. Fortu-
nately, this was facilitated by the merger of several
primary care trusts which happened just before the trial
began. This extended the area for which the trial had reg-
ulatory approval. An application was also made for the
trial to be included within the National Institute for
Health Research (NIHR) clinical research network portfo-
lio. This enabled the UK Primary Care Research Network
to provided practical assistance by helping to recruit the
final few practices.
Attrition and data collection
Of the 70 people recruited into the study one participant
has died due to an unrelated medical condition and three
others have withdrawn from the trial entirely. From the
remainder, 56 people have finished all aspects of the trial
and 10 others are currently completing the final treatment
phases of the study. Excluding the four people mentioned
initially, all participants have been successfully followed
up after each treatment phase, providing complete ques-
tionnaire data to date. The exceptionally high completion
rate for questionnaires observed so far is almost certainly
attributable to the use of home visits as the main follow
up method, which has helped to maintain commitment
amongst participants and fostered trust with the principal
investigator. Participants have also showed great enthusi-
asm for the study, which has been demonstrated by their
overall willingness to have repeated blood samples taken
at their general practice.
Study devices and packaging Figure 3
Study devices and packaging. Photograph of MagnaMax® 
insert, copper bracelet, and materials used in packaging 
devices.Trials 2008, 9:53 http://www.trialsjournal.com/content/9/1/53
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The inclusion of distant practices has made running the
trial somewhat more complex than expected, requiring
collaboration from additional haematology and bio-
chemistry departments across different acute trusts. Data
collection has also proved to be highly time consuming
due to the need for repeated home visits in a large geo-
graphical area across which some participants live more
than 100 miles apart.
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